Navigation Links
Treatment in Biological Technology

Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results

... trial evaluating the use of CPP-109 for the treatment of cocaine addiction and our proof-of-concept study evaluating the use of CPP-109 for the treatment of methamphetamine addiction," continued Mr. ... Placebo-Controlled Trial of Vigabatrin for the treatment of Cocaine Dependence in Mexican Parolees," was ...

NeurogesX Reports Second Quarter 2009 Results

... European Commission (EC) approval of Qutenza for treatment of peripheral neuropathic pain in non-diabetic ... Qutenza in all 27 EU-member countries for the treatment of peripheral neuropathic pain in non-diabetic ... currently approved in the European Union for the treatment of neuropathic pain in non-diabetic adults, ...

InterMune Reports Second Quarter 2009 Financial Results and Business Highlights

... physician prescriptions of Actimmune for the treatment of idiopathic pulmonary fibrosis (IPF), which ... lower off-label sales of Actimmune for the treatment of IPF, which InterMune does not promote. ... with and supportive of CAPACITY 2. treatment effect in the CAPACITY studies was also generally ...

OncoGenex Reports Second Quarter 2009 Financial Results

... phase 1 clinical trial evaluating OGX-427 treatment in patients with bladder cancer; and - ... used to compare the death rates between treatment groups, was 0.61, representing a 39% lower rate ... of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology ...

Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody

... of colon and breast cancer, we observed that treatment with OMP-21M18 significantly decreased the ... in treated tumors. Results demonstrate that treatment with OMP-21M18 as a single agent or in ... cells found in colon and breast tumors. Notably, treatment with chemotherapy alone was demonstrated to ...

Repligen Reports First Quarter Fiscal Year 2010 Financial Results

... ducts is important in the diagnosis and treatment of diseases such as acute and chronic ... McLean Hospital for the use of uridine in the treatment of patients with bipolar disorder. If issued, ... of histone deacetylase enzymes (HDACs) for the treatment of inherited neurodegenerative diseases such as ...

Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results

... important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal ... important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal ... completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) ...

Amicus Therapeutics Announces Second Quarter 2009 Financial Results

... closer to bringing to market an important, novel treatment to patients who suffer with Fabry disease." ... Amigal (TM) (migalastat hydrochloride) for the treatment of Fabry disease In the second quarter of ... double-blind, randomized, placebo-controlled treatment stage and will enroll approximately 60 subjects ...

Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results

... its investigational product candidate for the treatment of acute pain and fever. The NDA was ... Review, reflecting the unmet medical need for the treatment of pain and fever in patients who cannot take ... an investigational product candidate for the treatment of acute pain and fever. For more information ...

Pharmasset to Present at Canaccord Adams Conference

... on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(R) for the treatment of human immunodeficiency virus (HIV). Our ... Phase 1 clinical studies and Racivir, for the treatment of HIV, which has completed a Phase 2 clinical ...

Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock

... in the discovery and development of drugs for the treatment of human viral diseases, today announced the ... in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of hepatitis C virus. Idenix ...

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

... of velaglucerase in naïve Gaucher patients. A treatment protocol for early access has been approved by ... DEVELOPMENTS Products VYVANSE - for the treatment of ADHD - On May 1, 2009 Shire and GSK ... with the aim of improving recognition and treatment of ADHD in adults. - On June 1, 2009 Shire ...

Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients

... and at 18 months, a statistically significant treatment effect on the primary endpoint emerged, while ... should maximize the potential for the greatest treatment effect in our upcoming Phase 2 trial." ... control physical movements. There is currently no treatment that can reverse the degeneration of these ...

Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Radezolid in Community-Acquired Pneumonia

... commercialization of novel antibiotics for the treatment of antibiotic-resistant infections, today ... from a Phase 2 clinical trial of radezolid in the treatment of community-acquired pneumonia (CAP). In ... to offer a safe therapeutic alternative for the treatment of methicillin-resistant Staphylococcus aureus ...

Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update

... Phase 2 trial of picoplatin for the first-line treatment of metastatic CRC at the 2009 American Society of ... 2 clinical trial of picoplatin for the first-line treatment of patients with metastatic CRPC at the 2009 ASCO ... doses of docetaxel and prednisone, the standard treatment for CRPC. In addition, no neurotoxicity was ...

Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress

... commercialize additional tests to personalize the treatment of cancer. Since 2004, we have delivered Onco ... breast cancer test was used to guide chemotherapy treatment indicating that breast cancer in men displays ... physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched the ...

Micromet Closes $80.5 Million Public Offering of Common Stock

... developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, ... developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. ... (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia ...

Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure

... study of its lead product, CD-NP, for the treatment of acute heart failure. The single-blind, ... company that develops innovative products for the treatment of cardiovascular disease and other areas of ... chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally ...

VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference

... to complete Phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in Phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual ... of Luramist(TM), its drug candidate for the treatment of hypoactive sexual desire disorder (HSDD) in ...

Sanofi-aventis U.S. Introduces BenzaClin(R) Carekit

... acne, the arrival of the carekit offers an acne treatment and a moisturizer under one easy to write ... BenzaClin is a topical, prescription acne treatment that combines the acne-fighting power of benzoyl ... or benzoyl peroxide alone for the topical treatment of acne. With BenzaClin(R), improvements have ...

DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD

... 17,21-dipropionate, or orBec((R))) for the treatment of gastrointestinal symptoms associated with ... to develop safe and effective therapies for the treatment of rare diseases and disorders. In addition to ... ingredient in inhalation products for the treatment of patients with allergic rhinitis and asthma. ...

Biotech Hot in July Driven by Positive Drug Data and Acquisitions

... potentially clearing the way for the first new treatment against the inflammatory disease for over 50 years. Patients taking Benlysta plus a standard treatment for one year had reduced symptoms - including ... - compared with patients taking standard treatment plus placebo. The study involved more than 860 ...

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

... developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, ... are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating ... from rare diseases access to the same quality of treatment as other patients. (1) Topp, M.S. et al ...

Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer

... that clinical data relating to long-term treatment with Stimuvax were presented at the International ... Ontario, involved 16 patients who received treatment with Stimuvax for between 2 and 8.2 years as part ... discontinued Stimuvax after 2.0 to 5.1 years of treatment as a result of disease progression and are ...

Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia

... for Restanza(TM) (cethromycin) for the outpatient treatment of adults with mild-to-moderate community ... Restanza demonstrated safety for the outpatient treatment of adults with mild-to-moderate CAP, but voted that Restanza did not demonstrate efficacy in the treatment of CAP. The committee's negative vote on the drug ...

Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit

... which is approved in the United States for the treatment of chronic lymphocytic leukemia (CLL) and for the treatment of patients with indolent B-cell non-Hodgkin's ... has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen ...

Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients

... at weeks 4 and 12 will be randomized to stop all treatment at week 24 or 48. The primary endpoint of the ... weeks 24 and 48, and 24 weeks after stopping all treatment (defined as S ustained V irological R esponse, ... including twelve weeks of triple combination treatment and a randomized exploration of shortening the ...

Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights

... care by developing novel medicines for the treatment of hepatitis C, today reported its financial ... continue advancing the development of ANA598 as a treatment for chronic hepatitis C," said Steve Worland, ... including twelve weeks of ANA598 combination treatment and a randomized exploration of shortening the ...

Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors

... growth factor-B (PDGF-B) protein as a treatment for patients with non-healing diabetic foot ... received FDA approval in November 2005 for the treatment of periodontal bone defects. GEM 21S, which is ... evaluate the Excellarate product candidate as a treatment for patients with non-healing diabetic ulcers. ...

Micromet Announces Pricing of Public Offering of Common Stock

... developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, ... developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. ... (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia ...

Transave Enters Into Cooperative Research Agreement With NIH To Study ARIKACE(TM) In Nontuberculous Mycobacteria

... failed to respond to standard, guideline-based treatment regimens. The study will assess the safety and ... NTM lung disease in the United States. Current treatment requires lengthy multi-drug regimens that are ... Few clinical trials are under way to identify treatment recommendations, and no new drugs have been ...

Endo Pharmaceuticals Reports Strong Second Quarter 2009 Financial Results

... ((R)) LA: SUPPRELIN LA is indicated for the treatment of central precocious puberty (CPP). Endo ... severe pain; FROVA(R) tablets for the acute treatment of migraine attacks with or without aura in ... requiring continuous, around-the-clock opioid treatment for an extended period of time; and Voltaren(R) ...

Micromet Announces Public Offering of Common Stock

... developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, ... developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. ... (MT103) is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia ...

Sangamo BioSciences Reports Second Quarter 2009 Financial Results

... Therapeutic(TM) program to develop SB-509 as a treatment for diabetic neuropathy (DN) at the 69th Annual ... Phase 2 clinical trials demonstrated that SB-509 treatment resulted in statistically significant and ... titled "Zinc Finger Nucleases for In Vivo treatment of HIV Infection." Promotion of Philip D. ...

Elagolix Successful in Six Month Lilac Petal Study; Safety and Efficacy Confirmed in Patients With Endometriosis

... (DXA) scanning. Over the six month treatment period, elagolix 150 mg once daily had minimal ... scale which reveals the impact of treatment on a variety of health outcome domains. The core ... ECG testing evident for either dose of elagolix; treatment over six months was generally safe and well ...

First U.K. Stem Cell Awareness Rally to Take Place in Manchester, England on August 9th, 2009

... cell advocate. Peter states, "I visited stem cell treatment facilities and spoke at length with patients and ... Macie, who regained vision after stem cell treatment in China. Macie, at 15 years old, was denied a ... (ONH) had left her legally blind. After stem cell treatment in China, Macie returned to the States and one ...

Sunesis Reports Financial Results for the Second Quarter 2009

... of the study patients have also failed prior treatment with Doxil(R). Three dose cohorts of voreloxin ... were both platinum resistant and also had failed treatment with Doxil(R) is 90 days. In ... kinase inhibitor development candidate for the treatment of cancer. Biogen Idec is currently conducting ...

Sanofi-aventis Announces Second Quarter 2009 Results

... driven by its use in adjuvant breast cancer treatment and in prostate cancer. Growth was good across ... in combination with Taxotere((R)) as a first line treatment for women with metastatic breast cancer, based on ... cancer market as an adjuvant and as a first-line treatment in the metastatic phase, achieved second-quarter ...

United States FDA Clears the REGEN Trial to Test Bioheart's Combination Gene and Stem Cell Therapy in Heart Failure Patients

... of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead ... includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell ... an autologous, adipose tissue-derived stem cell treatment for acute heart damage, and MyoCell((R)) SDF-1, a ...

Cynosure Reports Second Quarter 2009 Financial Results

... of a broad array of light-based aesthetic treatment systems, today announced financial results for ... Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other ... used in this release exclude the accounting treatment of stock-based compensation, these non-GAAP ...
Other Contents
(Date:11/21/2014)... , Nov. 20, 2014   Atmel® Corporation ... microcontroller (MCU) and touch technology solutions, today launched the ... with the widest V cc range from ... accuracy and faster I 2 C bus communication speeds, ... EEPROM memory making them ideal for consumer, industrial, computer, ...
(Date:11/18/2014)... BETHESDA, Md. , Nov. 17, 2014 The ... European and U.S. regulatory agencies will speak and at least ... Quality Metrics Conference at the Omni Shoreham Hotel in ... is pleased once again to have significant support from the ... and Europe in our effort to ...
(Date:11/12/2014)... Nov. 12, 2014 Crossmatch™, a leading provider ... U.are.U ® fingerprint readers have been deployed throughout ... Central Mexico . The bakery chain implemented ... payroll issues caused by employees clocking in for each ... fingerprint readers, Montparnasse relied on paper timecards and a ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
(Date:12/20/2014)... 20, 2014 Parker & Sons, Inc. ... years of experience in contractor services announces reaching a ... for the homeowners of Arizona. Parker and Sons is ... contractor technicians that make customer service the number one ... Arizona and started with one service vehicle and has ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 Sub Zero Ice ... sponsor a blood drive Sunday the 28th from 2pm-6pm at ... & Sawyer Road in Sarasota, FL. , Inquiries regarding time ... you for participating in the donating process, Sub Zero Ice ... flash frozen, custom ice cream. , About Sub Zero Ice ...
(Date:12/19/2014)... 2014 Eufaula, Oklahoma, located just 9 ... the state’s largest lake with more than 600 miles ... to a little more than 3,000 residents, hosted its ... the 6th of December. , Featuring Santa, Christmas lights ... Eufaula on Main Street. Narconon Arrowhead’s parade float ...
(Date:12/19/2014)... warns parents that buying an older car for their teens may ... drivers killed in the United States between 2008 and 2012 were ... lacked important safety features that are available on newer cars, the ... were in cars at least six years old, 34 percent were ... cars 11 to 15 years old, and 17 percent were in ...
(Date:12/19/2014)... 2014 (HealthDay News) -- Dense bunches of bacteria called biofilms ... new study finds. The researchers said these biofilms ... The presence of these biofilms may represent an increased ... to predict a person,s risk for the disease, the researchers ... these biofilms may coat the mucus layer of cells lining ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 2Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 3Health News:Shark Tank’s Sub Zero Ice Cream Sponsors Blood Drive 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 2Health News:Narconon Arrowhead Debuts Float at Checotah and Eufaula Christmas Parades 3Health News:Older Cars a Bad Choice for Younger Drivers 2Health News:Could Bacteria Play a Role in Colon Cancer? 2
Other TagsOther Tags